WO2023100159 - MULTICISTRON EXPRESSION VECTOR FOR COVID-19 VACCINE
National phase entry:
Publication Number
WO/2023/100159
Publication Date
08.06.2023
International Application No.
PCT/IB2022/061742
International Filing Date
03.12.2022
Title **
[English]
MULTICISTRON EXPRESSION VECTOR FOR COVID-19 VACCINE
[French]
VECTEUR D'EXPRESSION DE MULTICISTRON POUR VACCIN CONTRE LA COVID-19
Applicants **
KASHIV BIOSCIENCES, LLC
Inventors
GUPTA, Sudharti
NARAYAN, Om
PONNAPU REDDY, Narahari
RAWAL, Chandramauli
JOSHI, Kaushal
Priority Data
202121056210
03.12.2021
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2762 | |
| EPO | Filing, Examination, Granting | 20726 | |
| Japan | Filing, Examination, Granting | 2678 | |
| South Korea | Filing, Examination, Granting | 3258 | |
| USA | Filing, Examination, Granting | 6710 |
Total:
36,134
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention provides an expression vector comprises gene of interest encode more than one structural protein to enhance immune responses against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants. Further, the present invention the expression vector comprises spike protein of SARS-CoV-2 and one or more structural protein selected from membrane protein, envelope protein and nucleocapsid protein of SARS-CoV-2. The expression vector expressed mRNA capable to encode more than one structural protein to provide immune response against SARS-CoV-2 virus.[French]
La présente invention concerne un vecteur d'expression comprenant un gène d'intérêt codant pour au moins deux protéine structurale afin d'améliorer les réponses immunitaires contre le coronavirus 2 du syndrome respiratoire aigu sévère (SARS-CoV-2) et ses variants. En outre, la présente invention concerne le vecteur d'expression comprenant une protéine de spicule du SARS-CoV-2 et une ou plusieurs protéines structurales choisies parmi la protéine membranaire, la protéine d'enveloppe et la protéine de nucléocapside du SARS-CoV-2. L'ARNm exprimé par un vecteur d'expression peut coder plus d'une protéine structurale pour fournir une réponse immunitaire contre le virus du SARS-CoV-2.